Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model

A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas

(2015) Yazmín Odia et al.   JOURNAL OF NEURO-ONCOLOGY

Development of the Metronomic Biofeedback Pump for leptomeningeal carcinomatosis: technical note

(2015) Thomas C. Chen et al.   JOURNAL OF NEUROSURGERY

Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis

(2015) YANG ZHANG et al.   ONCOLOGY REPORTS

From Bortezomib to other Inhibitors of the Proteasome and Beyond

(2013) Daniela Buac et al.   CURRENT PHARMACEUTICAL DESIGN

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis

(2013) Daniela A. Bota et al.   JOURNAL OF NEUROSURGERY

In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma

(2013) Susanna J. E. Veringa et al.   PLoS One

Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies

(2012) Sameer Agnihotri et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: A mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis

(2011) Dai-Wu Seol   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions

(2011) Sarit Kahana et al.   CELLULAR SIGNALLING

Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation – incidence, therapeutic strategies, and outcome

(2011) Lutz Dörner et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Frameless multimodal image guidance of localized convection-enhanced delivery of therapeutics in the brain

(2011) Imramsjah M J van der Bom et al.   Journal of NeuroInterventional Surgery

Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

(2011) Daniel R. Premkumar et al.   MOLECULAR CARCINOGENESIS

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

(2011) B. B. Friday et al.   NEURO-ONCOLOGY

Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy

(2011) X. Gong et al.   NEUROLOGY

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models

(2009) M. J. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

Bortezomib in the front-line treatment of multiple myeloma

(2008) Paul G Richardson et al.   Expert Review of Anticancer Therapy